Abstract
Background During the current pandemic, healthcare professionals (HCP) have been at the frontline of the crisis. Serological screening may help in identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence. However, given the rapidly evolving situation in spring 2020, many questions regarding coronavirus disease 2019 (COVID-19) infection risk and utility of serological testing remained unanswered. To address these questions, we initiated the COVID-19 Contact (CoCo) study at Hannover Medical School, a large university hospital in Northern Germany and affiliated care providers.
Methods The CoCo study is an ongoing, prospective, longitudinal, observational study in HCP and individuals with potential contact to SARS-CoV-2. It monitors anti-SARS-CoV-2 immunoglobulin serum levels and collects information on symptoms of respiratory infection, work and home environment, and self-perceived SARS-CoV-2 infection risk. Inclusion criteria are (1) working as HCP in clinical care at our university centre, affiliated hospitals or private practices, (2) written informed consent and (3) age >18 years. Exclusion criteria are (1) refusal to give informed consent and (2) contraindication to venepuncture. Study participants are asked to provide weekly to six-monthly samples (7.5 ml serum and 7.5 ml EDTA blood) and fill out a questionnaire. Since March 2020, around 1250 HCP have been included in the study. At each study visit, sera are screened for anti-SARS-CoV-2 spike protein 1 (S1) immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA). Positive or borderline positive samples are re-assessed with an alternative serological test. Individual results for each study participant are made available online via a dedicated study website. This study also aims to compare different serological testing assays, as well as explore further humoral and cellular immune markers. Study protocols are continually adapted to the rapidly evolving situation of the current pandemic.
Discussion This ongoing prospective study will aim to answer central questions on the prevalence and kinetics of anti-SARS-CoV-2-humoral immune responses and the validity of serological testing of HCP in a region with high healthcare standard and comparatively low COVID-19 prevalence. As such, our results are highly relevant to other regions and may support HCP around the world in managing this unprecedented situation.
Trial registration German Clinical Trial Registry, DRKS00021152. Registered 4th April 2020 -retrospectively registered, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021152
Competing Interest Statement
The CoCo study received seed funding by local patient organizations and clinical and research communities such as the Rheumazentrum and Verein Kinderherz Hannover. This work was supported by Novartis grant number MAIN457A_FVKH012 and earmarked donations by Gilead, PARI and Verein Kinderherz Hannover. The funders have no influence on study design, data collection and analysis, decision to publish, or preparation of manuscripts.
Clinical Trial
DRKS00021152
Funding Statement
The CoCo study received seed funding by local patient organizations and clinical and research communities such as the Rheumazentrum and Verein Kinderherz Hannover. This work was supported by Novartis grant number MAIN457A_FVKH012 and earmarked donations by Gilead, PARI and Verein Kinderherz Hannover. The funders have no influence on study design, data collection and analysis, decision to publish, or preparation of manuscripts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
. Ethical approval from the Institutional Review Board of Hannover Medical School and data security management approval has been secured (approval # 8973_BO_K_2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Technical appendix, statistical code, and dataset available from the corresponding author (behrens.georg@mh-hannover.de)
Abbreviations
- COVID-19
- coronavirus disease 19
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- WHO
- world health organization
